ClinicalTrials.gg
Active, not recruitingNCT06289621Updated Nov 18, 2026

Brief Transdiagnostic Treatment for Anxiety Disorders and Post-traumatic Stress Disorder (PTSD) in South Africa

An interventional study of False Safety Behavioral Elimination Treatment (FSET) and Enhanced Standard Care in Anxiety Disorders and Post-traumatic Stress Disorder, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Anxiety Disorders by Massachusetts General Hospital — 14 open to participants now, 20 under way, none of them phase 3. Anxiety Disorders · Massachusetts General Hospital.

Planned enrollment
33rd of 64
60 · median 63
Started
2024
with 5 others
No phase
40 of 67
12 open now
Primary completion
2026-10
later than 4 of 19 live
Registered
56th of 67
by date

Among the 67 studies in Anxiety Disorders by Massachusetts General Hospital, this one is the 33rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2024, is one of 40 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 56th registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

14 of the 67 studies in Anxiety Disorders by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Anxiety Disorders by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to examine the use of a brief transdiagnostic treatment for anxiety disorders and (post-traumatic stress disorder (PTSD) in South Africa. The intervention will be delivered by non-specialist providers (e.g., nurses) in primary care clinics. The brief intervention group will be compared to an enhanced standard care control group.

Read the detailed description

Post-traumatic stress disorder (PTSD) and anxiety disorders are highly prevalent and a leading cause of disability in low and middle-income countries (LMICs). Despite the development of evidence-based treatments (EBTs), an overwhelming majority of those in need (i.e., 85%) in LMICs do not receive treatment and, when they do, it is not empirically based. Despite the clear need for EBTs in LMICs, there are three primary barriers associated with the implementation of EBTs in these areas. These barriers include: (1) EBTs tend to be single disorder focused only treating one disorder at a time, (2) they are long in duration (e.g., 12-16 treatment sessions to treat one disorder), and (3) they tend to be complex and require a high level of skill to administer. Given the low availability of highly trained providers in LMICs, using an approach that is brief, culturally congruent, and less complex than typical EBTs is ideal for reducing these barriers. The current study aims to evaluate the use of a brief transdiagnostic treatment for anxiety disorders and PTSD (False Safety Behavior Elimination Treatment; F-SET) in South African primary care clinics. The current study is a Type 1 hybrid effectiveness-implementation trial assessing the effectiveness of the adapted brief transdiagnostic intervention and to explore facilitators and barriers to implementation. The adapted intervention is being compared to an enhanced standard care control condition.

03

Conditions studied

  • Anxiety Disorders
  • Post-traumatic Stress Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with a primary anxiety disorder (panic disorder, generalized anxiety disorder, social anxiety disorder, or obsessive-compulsive disorder) or post-traumatic stress disorder.

Exclusion criteria

Exclusion Criteria:

  • Participants who are acutely suicidal, have severe alcohol of substance use disorder, or are engaged in another form of psychotherapy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Anxiety Disorders and Post-traumatic Stress Disorder (PTSD) Transdiagnostic Treatment ( FSET)

    The anxiety disorders and post-traumatic stress disorder (PTSD) transdiagnostic treatment (FSET) is brief, 5-session, cognitive-behavioral intervention designed to treat symptoms associated with anxiety disorders and PTSD. The treatment is administered by lay providers (e.g., nurses) in primary care clinics in South Africa.

    Behavioral: False Safety Behavioral Elimination Treatment (FSET)

  • Other
    Enhanced Standard Care Group

    The enhanced standard care group is the condition. Those in the enhanced standard care control group will receive standard care plus referrals. Upon completion of the study, they will be offered the anxiety disorder and post-traumatic stress disorder treatment (FSET).

    Behavioral: Enhanced Standard Care

Interventions

  • BehavioralFalse Safety Behavioral Elimination Treatment (FSET)

    5-session transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD)

  • BehavioralEnhanced Standard Care

    Participants in the enhanced standard care control group will receive treatment as usual and a list referrals.

06

What researchers measure

Primary outcomes

  1. Structured Clinical Interview for the DSM-5 (SCID-5)

    Diagnostic assessment assessing the presence or absence of a mental health diagnosis.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

  2. Clinician-Administered PTSD Scale for the DSM-5 (CAPS)

    Diagnostic assessment assessing the presence or absence of post-traumatic stress disorder (PTSD)

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

  3. Work Social Adjustment Scale (WSAS)

    Assessment of functional impairment. Scores range from 0 to 40 with higher scores indicating higher levels of functional impairment.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

  4. General Anxiety Disorder-7 (GAD-7)

    General measure of anxiety. Scores range from 0 to 21 with higher scores indicating greater level of anxiety.

    Time frame: pre-treatment, immediately after the last treatment session, and 3-month follow-up

  5. Beck Anxiety Inventory (BAI)

    Measure of anxiety symptoms. Scores range from 0 to 63 with higher scores indicating greater levels of anxiety.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

  6. Safety Aid Scale (SAS)

    Assessment of safety aid utilization and avoidance in anxiety disorders and PTSD. Higher scores indicate greater safety aid utilization.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

Secondary outcomes

  1. Post-traumatic Disorder Checklist (PCL-5 PTSD Checklist (PCL-5)

    PTSD symptom measure. Scores range from 0 to 80 with higher scores indicating greater level of post-traumatic stress symptoms.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

  2. Patient Health Questionnaire - 9 (PHQ-9)

    Measure of emotional distress. Scores range from 0 to 20 with higher scores indicating greater emotional distress.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

  3. Beck Depression Inventory (BDI)

    Measure of depressive symptoms. Scores range from 0 to 63 with higher scores indicating greater levels of depression.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

  4. Anxiety Sensitivity Index -3

    Assessment of anxiety sensitivity. Scores range from 0 to 72 with higher scores indicated higher levels of anxiety sensitivity.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

Other outcomes

  1. Life Events Checklist (LEC)

    Assessment of exposure to traumatic events. Endorsement of events indicates the degree to which one has been exposed to traumatic events.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

  2. Alcohol Use Disorders Identification Test (AUDIT)

    Assessment of alcohol use. Scores range from 0 to 40 with higher scores indicating possible problematic alcohol use.

    Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up

07

Study locations

1 site
08

References and documents

Publications

  • Riccardi CJ, Korte KJ, Schmidt NB. False Safety Behavior Elimination Therapy: A randomized study of a brief individual transdiagnostic treatment for anxiety disorders. J Anxiety Disord. 2017 Mar;46:35-45. doi: 10.1016/j.janxdis.2016.06.003. Epub 2016 Jun 18. PubMed 27397584 ↗
  • Korte KJ, Norr AM, Schmidt NB. Targeting Safety Behaviors in the Treatment of Anxiety Disorders: A Case Study of False Safety Behavior Elimination Treatment. Am J Psychother. 2018 Jul 1;71(1):9-20. doi: 10.1176/appi.psychotherapy.20180001. Epub 2018 May 7. PubMed 29733676 ↗
  • Schmidt NB, Buckner JD, Pusser A, Woolaway-Bickel K, Preston JL, Norr A. Randomized controlled trial of false safety behavior elimination therapy: a unified cognitive behavioral treatment for anxiety psychopathology. Behav Ther. 2012 Sep;43(3):518-32. doi: 10.1016/j.beth.2012.02.004. Epub 2012 Mar 9. PubMed 22697441 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Oct 2026, 29 months.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 29 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jul 2026 → Oct 2026 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Mar 4, 2024
StartActual
May 8, 2024
Primary completionActual
Oct 9, 2026was Jul 2026
CompletionEst.
Jun 30, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 18, 2026
Primary completion
Jul 31, 2026→Oct 9, 2026 (actual)
Nov 18, 2026
Study completion
Dec 31, 2026→Jun 30, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 31, 2026→Oct 9, 2026 (now actual)
    Study completion Dec 31, 2026→Jun 30, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06289621
Collaborators
University of Stellenbosch, Fogarty International Center of the National Institute of Health, Harvard Medical School (HMS and HSDM)
Responsible party
Kristina Korte (Assistant Professor, Massachusetts General Hospital) — Principal investigator
First posted
Mar 4, 2024
Start date
May 8, 2024
Primary completion
Oct 9, 2026
Completion
Jun 30, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion